Comparaison en France, en Italie et en Espagne des modalités de prise en charge de la maladie thromboembolique veineuse

Maurizot, A.; Bura-Rivière, A.; Gritli, K.; Bertoletti, Laurent; Hernández‐Blasco, Luis; Ciammaichella, Maurizio; Díaz-Pedroche, Carmen; Maria, Andrea De; Lorente, Manuel; Monréal, Manuel

doi:10.1016/j.jdmv.2017.01.002

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20,25] Recent data from the RIETE study have shown that among patients with VTE, LMWH is the most frequently used drug as initial therapy in France, Italy and Spain. [30] These data suggest that despite clinical trials have shown that rivaroxaban exhibit a better benefit-risk profile than standard therapy in a wide spectrum of the VTE population (only 18% of our patients did not meet criteria to be included in the EINSTEIN studies), [13–15] and that in contrast to some other DOACs, rivaroxaban can be used in the acute setting without parenteral anticoagulation, [31] the use of rivaroxaban in this context is still low and limited to some type of patients. This may be related with the lack of reimbursement of rivaroxaban for this indication in Spain.…”

Section: Discussionmentioning

confidence: 99%

Rivaroxaban for the treatment of venous thromboembolism in real life

Demelo‐Rodríguez

Galeano‐Valle

García-Fernández-Bravo

et al. 2019

Medicine

View full text Add to dashboard Cite

The clinical profile, evolution and complications of treatment with rivaroxaban in a cohort of patients presenting with venous thromboembolism (VTE) were analyzed in an observational, non-interventional and prospective study.A total of 111 patients were included in the study. Clinical data were collected from the medical history of the patients and recorded in a specific database.Mean age was 63.8 ± 17.4 years, 53.2% of patients were men, 55.9% had at least another concomitant condition, and 40.9% at least 1 VTE risk factor. 54.1% of patients presented with deep venous thrombosis, 32.4% with pulmonary embolism and 13.5% with both conditions simultaneously. The 61% of patients were admitted to hospital and mean hospital length-of-stay was 8.8 ± 9.9 days. After a mean follow-up 530 ± 464 days (median follow-up of 405 days), 3.9% of patients died and VTE recurrence occurred in 2.9% of patients. While receiving rivaroxaban, a first bleeding complication occurred in 8.1%; all events were minor bleeding.Our study supports the current literature data and confirms the similar results of real-life VTE patients with those enrolled in the rivaroxaban pivotal clinical trials. Rivaroxaban may facilitate outpatient treatment and might be considered as a first-line therapy for the management of VTE patients.

show abstract